News for Lipocine Inc. (LPCN)

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveragi

Lipocine reports FY revenue of $11.19M and GAAP EPS of $0.00. Discover financial highlights and insights into the company's performance.

PR NewswireSALT LAKE CITY, March 12, 2025 SALT LAKE CITY, March 12, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveragi

PR NewswireSALT LAKE CITY, Nov. 18, 2024 SALT LAKE CITY, Nov. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging

Lipocine Inc. (LPCN), a biopharmaceutical company, Thursday announced positive data from the Phase 1 study of oral brexanolone, a proprietary bioidentical neuroactive steroid (NAS) being developed for the treatment of post-partum depression (PPD).

Lipocine reports promising oral brexanolone study results

The rising demand for maternal mental health services is largely due to the increasing incidence of conditions like postpartum depression, dysthymia,...

Lipocine announces positive bioequivalence study results

Lipocine reports bioequivalence in oral PPD treatment study

Lipocine (LPCN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Lipocine (LPCN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake, and unhealthy...

Connecticut-based Rallybio Corporation (RLYB), a clinical-stage biotechnology company is up over 90 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Connecticut-based Rallybio Corporation (RLYB), a clinical-stage biotechnology company is up over 90 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

The rise in the number of people suffering from cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and...

Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP...

Statutory Accounts Director's Report In accordance with the Corporations Act 2001, the directors of...

/PRNewswire/ -- DelveInsight's Liver Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, liver cirrhosis...

Nonalcoholic fatty liver disease (NAFLD) is speedily becoming the most common cause of chronic liver disease, liver cirrhosis, hepatic decompensation,...